On the recordFebruary 3, 2016
I was concerned that CMS finalized its Part B payment policy for biosimilars last year combining all biosimilars into one average sales price calculation and payment code.
Source
congress.govEditor's note · Context
Pitts expresses concern over CMS's payment policy for biosimilars potentially harming market entry.
Share
More from Joe Pitts
Jul 11, 2016
One in five trauma deaths may be preventable or, in other words, about 30,000 people might be saved every year.
Dec 1, 2016
I thank the gentleman. As a member of the select investigative panel, I rise in support of H. Res. 933. Madam Speaker, after the release of the undercover videos of Planned Parenthood, one little known tissue procurement company became a…
Other voices in this conversation
